tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Blackham A and Griffiths RJ The effect of FK506 and cyclosporin A on antigen-induced arthritis. 1991 Clin. Exp. Immunol. pmid:1718639
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Fukuda T et al. Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. 1991 Int. Arch. Allergy Appl. Immunol. pmid:1718889
Murase N et al. FK 506 prevents spontaneous diabetes in the BB rat. 1991 Transplant. Proc. pmid:1703705
Meiser BM et al. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. 1991 Lancet pmid:1719321
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Ali Shah I et al. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. 1991 Transplant. Proc. pmid:1721276
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Rucay P et al. FK 506 rescue therapy for refractory acute rejection in five liver recipients. 1991 Transplant. Proc. pmid:1721340
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Schreiber SL Chemistry and biology of the immunophilins and their immunosuppressive ligands. 1991 Science pmid:1702904
Wasik M et al. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. 1991 Transplantation pmid:1702910
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Jacobs TW et al. The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. 1991 Transplant. Proc. pmid:1721403
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Steinmann B et al. Mechanism of action of FK 506 and cyclosporin. 1991 Lancet pmid:1704088
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Wada H et al. An attempt to induce tolerance to skin grafts in congenic mice with FK 506. 1991 Transplant. Proc. pmid:1721435
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Neuberger J FK 506--a promise of good things to come? 1991 Hepatology pmid:1711005
Halloran PF and Madrenas J The mechanism of action of cyclosporine: a perspective for the 90's. 1991 Clin. Biochem. pmid:1711939
Palaszynski EW et al. Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. 1991 Clin. Biochem. pmid:1711940
Matsuura T et al. [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. 1991 Hinyokika Kiyo pmid:1721767
Morris PJ Cyclosporine, FK-506 and other drugs in organ transplantation. 1991 Curr. Opin. Immunol. pmid:1721824
Lhoëst G et al. Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. 1991 Pharm Acta Helv pmid:1722046
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
McKeon F When worlds collide: immunosuppressants meet protein phosphatases. 1991 Cell pmid:1716181
Christians U et al. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. 1991 Clin. Biochem. pmid:1714802
Petros AM et al. NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. 1991 J. Med. Chem. pmid:1716684
Turka LA and Thompson CB Structure-function relationship of immunosuppressive drugs: a cautionary tale. 1991 Hepatology pmid:1714876
FK 506--an investigational immunosuppressant. 1991 Med Lett Drugs Ther pmid:1716722
Brizuela L et al. Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. 1991 Mol. Cell. Biol. pmid:1715022
Heitman J et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 1991 Science pmid:1715094
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702